Table 6 Frequencies of adverse events associated with NAIs from patient reviews in the WebMD.

From: Assessment of adverse events related to anti-influenza neuraminidase inhibitors using the FDA adverse event reporting system and online patient reviews

SOC terms

Oseltamivir, n (%) (N = 525)

Zanamivir, n (%) (N = 20)

Psychiatric disorders

162 (30.86)

0

Gastrointestinal disorders

157 (29.90)

10 (50.00)

Cardiac disorders

46 (8.76)

2 (10.00)

Nervous system disorders

41 (7.81)

3 (15.00)

Skin and subcutaneous tissue disorders

32 (6.10)

0

General disorders and administration site conditions

18 (3.43)

1 (5.00)

Respiratory, thoracic and mediastinal disorders

13 (2.48)

0

Musculoskeletal and connective tissue disorders

9 (1.71)

0

Othersa

47 (8.95)

4 (20.00)

  1. SOC, System Organ Classes; aEar and labyrinth disorders, Immune system disorders, Infections and infestations, Injury, poisoning and procedural complications, Metabolism and nutrition disorders, Product issues, Renal and urinary disorders, Reproductive system and breast disorders, Vascular disorders.
Back to article page